Raynaud's Phenomenon and Cancer Chemotherapy
Authors: M. E. SCHEULEN
Journal: Annals of Internal Medicine (1982)

Letters and Corrections1 February 1982Raynaud's Phenomenon and Cancer ChemotherapyM. E. SCHEULEN, M.D., C. G. SCHMIDT, M.D.M. E. SCHEULEN, M.D.Search for more papers by this author, C. G. SCHMIDT, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-96-2-256 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTo the editor: We read with interest Vogelzang and coworkers' article on Raynaud's phenomenon after combination chemotherapy for testicular cancer (1). Comparison of their experience with our investigations gives strong evidence that the incidence of Raynaud's phenomenon might be reduced or postponed by the administering of glucocorticoids during vinblastine-bleomycin chemotherapy.Vinblastine and bleomycin are very effective drugs in combination chemotherapy for patients with testicular cancer (2, 3). We have treated patients with testicular tumors since 1975 with vinbastine-bleomycin-containing regimens (4), and since 1977 with sequential combination chemotherapy with vinblastine-bleomycin and doxorubicin-cisplatin (5): vinblastine, 0. 2 mg/kg body weight per day...References1. VOGELZANGBOSLJOHNSONKENNEDY NGKB. Raynaud's phenomenon, a common toxicity after combination chemotherapy for testicular cancer. Ann Intern Med. 1981;95:288-92. LinkGoogle Scholar2. SAMUELSHOLOYEJOHNSON MPD. Bleomycin combination chemotherapy in the management of testicular neoplasia. Cancer. 1975;36:318-26. CrossrefMedlineGoogle Scholar3. EINHORNDONOHUE LJ. Cis-diamminedichloroplatinum, vinblastine and bleomycin combination chemotherapy in disseminated testicular cancer. Ann Intern Med. 1977;87:293-8. LinkGoogle Scholar4. SEEBERSCHEULENOSIEKAHOFFKENSCHMIDT SMRKC. Development of chemotherapy programs containing vinblastine, bleomycin, adriamycin, and cis-dichlorodiammineplatinum(II). In: CARTER SK, CROOKE ST, UMEZAWA H, eds. Bleomycin: Current Status and New Developments. New York: Academic Press; 1978:215-26. Google Scholar5. SCHEULENSEEBERSCHILCHERMEIERSCHMIDT MSRCC. Sequential combination chemotherapy with vinblastine-bleomycin and doxorubicin-dis-dichlorodiammineplatinum(II) in disseminated nonseminomatous testicular cancer. Cancer Treat Rep. 1980;64:599-609. MedlineGoogle Scholar1. SCHEULENSEEBERSCHILCHERMEIERSCHMIDT MSRCC. Sequential combination chemotherapy with vinblastine-bleomycin and doxorubicin-cis-dichlorodiammineplatinum(II) in disseminated non-seminomatous testicular cancer. Cancer Treat Rep. 1980;64:599-609. MedlineGoogle Scholar2. SCHEULENHIGISCHILCHERMEIERSEEBERSCHMIDT MMRCSC. Sequential combination chemotherapy with vinblastine/bleomycin and adriamycin/cis-dichlorodiammineplatinum (II) in non-seminomatous testicular cancer: I. Results of a prospective randomized phase III-study with 71 patients with disseminated disease (stage IV). Klin Wochenschr. 1980;58:811-21. MedlineGoogle Scholar3. SCHEULENBIERBAUMNIEDERLE MWN. Sequential combination chemotherapy with vinblastine/bleomycin and adriamycin/cis-dichloroplatinum (II) in non-seminomatous testicular cancer: II. Long term results of a study with 140 patients with retroperitoneal disease (stage II). Klin Wochenschr. 1980;58:823-8. CrossrefMedlineGoogle Scholar4. BOSLLANGEFRALEY GPE. Vinblastine, bleomycin and cis-diamminedichloroplatinum in the treatment of advanced testicular cardinoma: possible importance of longer induction and shorter maintenance schedules. Am J Med. 1980;68:492-6. CrossrefMedlineGoogle Scholar5. BOSLKWONGLANGEFRALEYKENNEDY GRPEB. Vinblastine, intermittent bleomycin, and single-dose cis-dichlorodiammineplatinum(II) in the management of stage III testicular cancer. Cancer Treat Rep. 1980;64:331-4. MedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: West German Tumor Center University of Essen Medical School D-4300 Essen-1 Federal Republic of Germany PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited ByLate complications of chemotherapy in testicular cancerRaynaud's SyndromeTwo Cases of Prolonged Tinnitus Successfully Treated with SoshikokitoVascular Toxicity of Antineoplastic AgentsTreatment of digital ischaemia associated with chemotherapy using the prostacyclin analogue IloprostCapillary microscopy is a potentially useful method for detecting bleomycin vascular toxicityRaynaud Syndrom — Raynaud Krankheit(?)Surviving Adult Cancers. Part 1: Physiologic EffectsLois J. Loescher, RN, MS, Deborah Welch-McCaffrey, RN, MSN, Susan A. Leigh, RN, BS, Barbara Hoffman, JD, Frank L. Meyskens Jr, MDThe Correlation of Vinblastine Pharmacokinetics to Toxicity in Testicular Cancer PatientsSpättoxizität nach der Therapie maligner HodentumorenAcute Vascular Ischemic Events After Cisplatin-Based Combination Chemotherapy for Germ-Cell Tumors of the TestisDONALD C. DOLL, M.D., ALAN F. LIST, M.D., F. ANTHONY GRECO, M.D., JOHN D. HAINSWORTH, M.D., KENNETH R. HANDE, M.D., DAVID H. JOHNSON, M.D.Vascular and other complications of chemotherapy for testicular cancerBeta-thromboglobulin and platelet-factor 4 in patients with cancer: Correlation with the stage of disease and the effect of chemotherapy 1 February 1982Volume 96, Issue 2Page: 256-257KeywordsBody weightCancer chemotherapyChemotherapyCombination chemotherapyDrugsPatientsRaynaud syndromeTesticular cancer Issue Published: 1 February 1982 PDF DownloadLoading ...